Carocell Bio

📍 London, United Kingdom🗓 Founded 2018👥 6 employees💰 Last funded Jun 2025

Biotechnology Research 🌐 carocellbio.com

Carocell Bio is revolutionising the treatment of skin-related inflammatory conditions with its peptide-based, next-generation approach to promoting healthier skin. Its pipeline of products, meant for topical application to the skin, is designed to interrupt the inflammatory cascade – potentially providing safer and novel therapeutic options to patients. This includes treating and preventing AD (eczema) and delaying skin ageing – a process strongly associated with inflammation. Carocell Bio’s therapeutic pipeline consists of a number of small proteins (called “peptides”) that target an enzyme known as mitogen-activated protein kinase (MAPK). MAPK plays a key role in inflammation. These peptides have been specially formulated for topical use. Its pipeline of products, meant for topical application to the skin, is designed to interrupt the inflammatory cascade – potentially providing safer and novel therapeutic options to patients. This includes treating and preventing AD (eczema) and delaying skin ageing – a process strongly associated with inflammation. Carocell Bio’s therapeutic pipeline consists of a number of small proteins (called “peptides”) that target an enzyme known as mitogen-activated protein kinase (MAPK). MAPK plays a key role in inflammation. These peptides have been specially formulated for topical use.

Total investors

Early stage

Mid stage

Late stage

2018

Founded